Contact the Editorial Desk

Editorial correspondence

Prime Peptide Labs welcomes correspondence on the research record: a citation we have quoted inaccurately, a regulatory status that has changed, or a peer-reviewed study about GHK-Cu, TB-500, or BPC-157 that belongs on the references page. Corrections that improve the accuracy of the reading room are the most useful messages we receive, and they are read carefully.

A note is easiest to act on when it names the page, quotes the exact passage in question, and points to a supporting citation — a DOI or PubMed ID wherever possible — so a proposed change can be checked against its source quickly.

Editorial mailbox: editors@primepeptidelabs.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, some requests sit outside what a reading room can take on. This is a literature reading room, not a clinic and not a shop, which means it cannot:

• weigh in on, endorse, or comment on human use of any peptide covered here;
• name a dose, schedule, or route for any individual;
• diagnose a condition or decide whether a research finding fits a particular person;
• sell, source, suggest, or help track down any compound from any supplier;
• counsel athletes under anti-doping rules, since two of the three peptides here are banned in sport.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Replies to editorial correspondence are not guaranteed and may be delayed; the mailbox is watched intermittently.